Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Race Oncology (RAC) is looking to raise $5.4 million in an oversubscribed placement alongside a new bonus offer
  • Under the placement, the company will issue around 1.8 million new shares at $3 each — a 2.3 per cent discount on its recent trading levels
  • Race has also announced a bonus option to existing eligible shareholders on the basis of one bonus option for every 20 shares held
  • Funds from the placement will be put towards developing the company's anti-cancer drug, Bisantrene
  • On the market, Race is up 5.21 per cent and is trading at $3.23 per share

Race Oncology (RAC) is looking to raise $5.4 million in an oversubscribed placement alongside a new bonus offer.

Under the placement, the company will issue around 1.8 million new shares for $3 each — a 2.3 per cent discount on its recent trading levels.

Participants in the placement will receive one free attaching option for every 20 new shares subscribed for.

Funds from the placement will provide Race with additional capital to be deployed towards its three-pillar strategy, through which the company is investigating its Bisantrene candidate as a potential precision oncology agent and a heart-friendlier chemotherapeutic.

Last month, the company revealed it is teaming up with The University of Newcastle to investigate the heart safety of its Bisantrene drug.

Race has also announced a bonus option to existing eligible shareholders on the basis of one bonus option for every 20 shares held.

"We thank our new and existing shareholders for their continuing support. We believe that this raise will accelerate our plans and rewards our loyal shareholders," CSO Dr Dainel Tillett said.

"Race remains efficient with our capital usage and will always be focused on achieving the best outcome for our shareholders and the patients who may be helped by Bisantrene," he added.

On the market, Race is up 5.21 per cent and is trading at $3.23 per share at 11:23 am AEST.

RAC by the numbers
More From The Market Herald
Gabon-focussed iron ore company Genmin (ASX:GEN) lists on ASX

" Argenica Therapeutics (ASX:AGN) lists on ASX

Argenica Therapeutics (AGN) has finished its first day of trade on the ASX, following a well supported initial public offering.
Creso Pharma (ASX:CPH) - Creso Pharma - The Market Herald

" Creso Pharma (ASX:CPH) completes US dual listing

Creso Pharma (CPH) is officially dual listed, after completing its listing on the US OTCQB stock exchange.
The Market Herald Video

" US regulator approves expanded use of Avita Medical’s (ASX:AVH) RECELL System

The US regulator has approved the expanded use of Avita Medical’s (AVH) RECELL system in combination with meshed autographs to treat burns patients.
Advanced Human Imaging (ASX:AHI) - CEO, Vlado Bosanac - The Market Herald

" Advanced Human Imaging (ASX:AHI) signs term sheet with Cubert

Advanced Human Imaging (AHI) has signed a binding term sheet with Toronto-based digital health provider Cubert Inc.